Author

Hiroko Yamakawa

Chordia Therapeutics Inc. (Japan)ORCID 0009-0003-5456-7643Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Akio Mizutani· 1 shared Daisuke MorishitaiD· 1 shared Hidekazu TokuharaiD· 1 shared Hiroshi Banno· 1 shared Kosuke KawaguchiiD· 1 shared Kosuke YusaiD· 1 shared Mariko TakanoiD· 1 shared Masakazu ToiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Akio Mizutani

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 20, 2026

CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade

Hiroko Yamakawa, Raghda Khatab, Akio Mizutani…·Kosuke Yusa

This study develops CTX-439, a CDK12/13 inhibitor, showing anti-tumor effects and resistance mechanisms, and proposes combining it with BCL-2 family inhibitors for cancer treatment.

2 citations

humanexperimental assay

𝕏 PostBluesky